ISSAQUAH, Wash.--(BUSINESS WIRE)--BaroPace Inc. announces its Phase I first-in-human trial of PressurePace TM, its patent-pending pacemaker control algorithm for the treatment of heart failure with ...

–Treatment with HU6 led to significant reductions in body fat and abdominal visceral fat while preserving skeletal muscle in patients with obesity-related heart failure with preserved ejection ...

Designation underscores the potential for VS-041 to address a significant unmet medical need and potentially improve diagnosis by utilizing a serum biomarker VS-041 is being evaluated in a Phase 1c ...

(RTTNews) - Tenax Therapeutics, Inc. (TENX) announced an expansion of its Phase 3 LEVEL program for TNX-103 or oral levosimendan, a novel treatment for pulmonary hypertension with heart failure with ...

A device you might want with you in an avalanche; why heart failure with preserved ejection fraction may be seen as a ...

CHICAGO — A new study has shown for the first time that a drug therapy can reduce major heart failure clinical outcomes in patients with heart failure and a preserved ejection fraction (HFpEF) and ...

Tectonic Therapeutic, Inc. announced positive interim results from its Phase 1b clinical trial of TX45, a long-acting Fc-relaxin fusion protein, which demonstrated significant improvements in left ...